Merck Acquiring Inspire Pharmaceuticals
April 7, 2011
Merck announced earlier this week that it will be acquiring Inspire Pharmaceuticals, which manufactures ophthalmic treatments such as AZASITE (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis, and ELESTAT (epinastine HCl ophthalmic solution) 0.05% for the prevention of ocular itching associated with allergic conjunctivitis.
Inspire also receives royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% and DIQUAS(TM) Ophthalmic Solution 3% (diquafosol tetrasodium) in Japan.
Merck described the acquisition as part of its long-term commitment to improving therapeutic options for the treatment of eye diseases.
Click here to read the full press release.
Comments
Jump down to form below to submit your own comments
